Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ROCKWELL MEDICAL, INC.RMTI · Entity 7426 | Director | March 19, 2018 | March 21, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ROCKWELL MEDICAL, INC.
Report date March 19, 2018 · Filed March 21, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.75 · Expires 2028-03-19 | Direct | 32,724 |
Reported balance
After 2018-03-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-03-19 · Grant · Acquired 32,724 · Balance 32,724 F1: The grant of these options is contingent upon shareholder approval of the 2018 Rockwell Medical, Inc. Long Term Incentive Plan (the "2018 Plan") at the Company's 2018 Annual Meeting of Shareholders. If the Company's shareholders do not approve the 2018 Plan, these contingent options are deemed null and void and may not be exercised by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: The grant of these options is contingent upon shareholder approval of the 2018 Rockwell Medical, Inc. Long Term Incentive Plan (the "2018 Plan") at the Company's 2018 Annual Meeting of Shareholders. If the Company's shareholders do not approve the 2018 Plan, these contingent options are deemed null and void and may not be exercised by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 19, 2018 Filed Mar 21, 2018 21:54 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantStock Option (Right to Buy) · Derivative | 32,724 | $0.00 Strike: $5.75 | $0.00 |
DisclosureSEC source: 0001140361-18-014496 · doc1.xml · derivative · entry 1 Bagley Patrick J · CIK 0001335829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,724 Underlying: Common Stock · 32,724 shares Expires 2028-03-19 F1 · security: The grant of these options is contingent upon shareholder approval of the 2018 Rockwell Medical, Inc. Long Term Incentive Plan (the "2018 Plan") at the Company's 2018 Annual Meeting of Shareholders. If the Company's shareholders do not approve the 2018 Plan, these contingent options are deemed null and void and may not be exercised by the reporting person. F1 · kind: The grant of these options is contingent upon shareholder approval of the 2018 Rockwell Medical, Inc. Long Term Incentive Plan (the "2018 Plan") at the Company's 2018 Annual Meeting of Shareholders. If the Company's shareholders do not approve the 2018 Plan, these contingent options are deemed null and void and may not be exercised by the reporting person. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 22:53 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001209191-17-066454 · doc4.xml · derivative · entry 5 Bagley Patrick J · CIK 0001335829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2017-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option became exercisable in three equal installments on December 17, 2008, December 17, 2009, and December 17, 2010. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 22:53 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | Tax withholdingCommon Stock | 49,243 | $6.60 | $325,003.80 |
DisclosureSEC source: 0001209191-17-066454 · doc4.xml · nonDerivative · entry 2 Bagley Patrick J · CIK 0001335829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,307 Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 22:53 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | Exercise / conversionCommon Stock | 50,000 | $6.50 | $325,000.00 |
DisclosureSEC source: 0001209191-17-066454 · doc4.xml · nonDerivative · entry 1 Bagley Patrick J · CIK 0001335829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 21, 2017 Filed Mar 23, 2017 22:44 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCommon Stock | 9,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-022667 · doc4.xml · nonDerivative · entry 1 Bagley Patrick J · CIK 0001335829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,550 F1 · shares: Performance-based stock grant. This grant vests upon the earliest to occur of any of the following (a) reported net sales of the company in any four consecutive calendar quarters equals or exceeds $100,000,000, (b) the market capitalization of the company is greater than $600,000,000 for ten consecutive trading days, or (c) one year following the date the Centers for Medicare & Medicaid Services assign the company transitional add on reimbursement payment status for the drug product, Triferic. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.